spironolactone and Tachycardia, Ventricular

spironolactone has been researched along with Tachycardia, Ventricular in 9 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

All Cause Hospitalization

Number of patients hospitalized for any reason during study follow-up. (NCT04495712)
Timeframe: through study completion, an average of 35 months

Kansas City Cardiomyopathy Questionnaire (KCCQ)

Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item reliable and valid questionnaire, which evaluates HRQOL in heart failure. It quantifies, in a disease-specific fashion, physical limitations, symptoms, quality of life, social interference and self-efficacy. KCCQ provides the calculation of 2 main scores, the overall score and the clinical summary score, which includes functional status, social limitation and quality of life domains scores. Range 0-100, higher scores represent higher HRQOL. (NCT04495712)
Timeframe: through study completion, an average of 35 months

Patient Concerns Assessment (PCA)

Patient Concerns Assessment (PCA) is a symptom checklist that measures physical symptoms and fears that are common after ICD implantation. The PCA is a disease-specific instrument for ICD QOL, symptoms, and distress, with a reliability of ( = 0.88). Range 0-44, a higher score reflects more concerns and fears. (NCT04495712)
Timeframe: 12 months

Short Form Health Survey Adapted for Veterans (SF36V)

Short Form Health Survey adapted for veterans (SF36V) is a 36 item questionnaire that measures general physical and mental health [17]. The SF36V is a reliable and valid questionnaire, containing eight constructs of health status: physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), general health perceptions (GH), energy/vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). These eight dimensions can be summarized numerically into two scores, the physical component summary (PCS) and the mental component summary (MCS). Range 0-100 higher score is better Health Related Quality of Life (HRQOL). We are reporting the Mental Component Summary score at 12 months here. (NCT04495712)
Timeframe: 12 months after enrollment

Time to First Appropriate Implantable Cardioverter Defibrillator (ICD) Therapy

Time to first documented ICD therapy for ventricular tachycardia or ventricular fibrillation after randomization (NCT04495712)
Timeframe: through study completion, an average of 35 months

Ventricular Refractoriness

The right ventricular effective refractory period (ERP) will be measured at 3 month in patients enrolled at the Portland VA Medical Center by single extra stimuli via their implanted defibrillator. The ERP is defined as the shortest paced beat coupling interval that fails to produce ventricular capture after a baseline stable pacing train. (NCT04495712)
Timeframe: measured 3 months after randomization

Trials

1 trial available for spironolactone and Tachycardia, Ventricular

Other Studies

8 other studies available for spironolactone and Tachycardia, Ventricular